logo
Buffer ETFs keep booming, and Wall Street is now betting investors want more options

Buffer ETFs keep booming, and Wall Street is now betting investors want more options

CNBC17-07-2025
Buffer ETFs are continuing to rake in cash from investors, and fund issuers have been rushing to create more variations to capitalize on the boom. The category had its biggest month of inflows ever in March and now has more than $70 billion in assets, according to data from ETF Action compiled by Strategas. Through June, the category was outpacing last year's flows and on track for another record year, even with a recent slowdown amid the stock market comeback. The basic version of a buffer fund looks like this: a fund gains exposure to a broad index, like the S & P 500 , using a combination of long-term options. The options are structured such that the fund loses nothing in certain downside scenarios, creating the "buffer," but in exchange gives up some upside in the event the market rallies. "For the most part, investors aren't necessarily looking to knock the lights out. They want to get a fair return and they want to protect their assets. They're concerned about the downside," ProShares CEO Michael Sapir. As the category has grown, the variety of funds has increased dramatically — both in timeline and risk profile. For example, Innovator launched funds last month that aim to generate positive returns during some market declines by effectively adding on a short position within the options strategy. A new ProShares suite of " dynamic " buffers reset every day, tapping into the zero-day options boom. Even Cathie Wood's Ark Invest has filed to launch buffer products built on the firm's notoriously volatile ETFs. Some of the ETFs are even pitched on more upside as opposed to downside protection. A series of FT Vest Accelerator funds trades some initial upside for amplified returns during big market rallies. "It's been well appreciated as the downside protection play, but there are other ways you can massage the distribution, if you may," said Karan Sood, CEO of Vest Financial, which is also the firm behind some of the most popular traditional buffer funds on the market. Performance and risks Buffer ETFs are an outgrowth of bespoke structured products and even mutual funds before them. The ETF category took off after 2022, which saw stocks and bonds fall in tandem and created an opening for a product that offered additional downside protection. Generally speaking, buffer ETFs seem to have performed well. A recent analysis by Morningstar's Jeffrey Ptak showed that buffer funds had generally succeeded over a five-year period ended in February. Still, there are risks. For one, the longer-term funds typically require an investor to buy on the launch or rebalance date and hold through the entire period to achieve the stated outcome. This is one reason for the variety of funds with different start dates, and can make comparing performance between ETFs tricky. The ProShares dynamic series is one potential solution here, though the funds are less than a month old and it remains to be seen if the daily rebalance strategy will satisfy investor demands for peace of mind. And even if a fund is delivering its stated returns, that might not be a smart move for every investor. Over multiyear periods, products with capped upside could underperform the broader market, even before accounting for the fees of buffer funds, which are typically higher than simple index products, often above 0.75% annually. These complicating factors make financial advisors the main audience for buffer products, and many of them are becoming "power users" and using multiple funds, Sood said. "A majority of the flow in our buffer ETFs is not coming from self-directed advisors but really from intermediaries — so financial advisors acting on behalf of their clients. They're the ones who are using buffer products," Sood said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cathie Wood buys $45 million of battered megacap tech stock
Cathie Wood buys $45 million of battered megacap tech stock

Yahoo

time14 minutes ago

  • Yahoo

Cathie Wood buys $45 million of battered megacap tech stock

Cathie Wood buys $45 million of battered megacap tech stock originally appeared on TheStreet. Cathie Wood doesn't give up on companies she believes in. The Ark Invest chief is known for sticking with tech stocks she sees as "disruptive", often buying even when they face setbacks. This is what she just did, adding to a high-profile tech stock amid a post-earnings dip. Wood's funds have experienced a volatile ride this year, swinging from sharp losses to strong gains. In January and February, the Ark funds rallied as investors bet on the Trump administration's potential deregulation that could benefit Wood's tech bets. But that momentum hit hard in March and April, with the funds trailing the market as top holdings slid amid growing concerns over the macroeconomy and trade policies. Now, the fund is regaining momentum. As of July 25, the flagship Ark Innovation ETF () is up 33.3% year-to-date, far outpacing the S&P 500's 8.6% gain. Wood's remarkable return of 153% in 2020 helped build her reputation and attract loyal investors. Her strategy can lead to sharp gains during bull markets but also painful losses, like in 2022, when ARKK tumbled more than 60%. As of July 25, Ark Innovation ETF, with $6.8 billion under management, has delivered a five-year annualized return of negative 0.03%. The S&P 500 has an annualized return of 16.46% over the same period. Cathie Wood's investment strategy explained Wood's investment strategy is straightforward: Her Ark ETFs typically buy shares in emerging high-tech companies in fields such as artificial intelligence, blockchain, biomedical technology and robotics. According to Wood, these companies have the potential to reshape industries, but their volatility leads to major fluctuations in Ark funds' Ark Innovation ETF wiped out $7 billion in investor wealth over the 10 years ending in 2024, according to an analysis by Morningstar's analyst Amy Arnott. That made it the third-biggest wealth destroyer among mutual funds and ETFs in Arnott's ranking. Wood recently said the U.S. is coming out of a three-year 'rolling recession' and heading into a productivity-led recovery that could trigger a broader bull market. In a letter to investors published in late April, she dismissed predictions of a recession dragging into 2026 and struck an optimistic tone for tech stocks. "During the current turbulent transition in the US, we think consumers and businesses are likely to accelerate the shift to technologically enabled innovation platforms including artificial intelligence, robotics, energy storage, blockchain technology, and multiomics sequencing," she said. But not all investors share this optimism. Through July 10, the Ark Innovation ETF saw nearly $2 billion in net outflows over the past 12 months, according to ETF research firm VettaFi. Cathie Wood buys $45 million of Tesla stock after earnings On July 24, the day when Tesla () dropped 8.2% following its second-quarter earnings, Wood's Ark funds snapped up 143,190 shares worth around $45.3 million. This was one of Wood's largest recent purchases. Tesla's Q2 earnings were quite dismal. The electric vehicle maker reported a 16% drop in automotive revenue as vehicle sales declined for the second straight company posted adjusted earnings of 40 cents per share, missing the 43 cents expected. Revenue came in at $22.50 billion, slightly below the $22.74 billion forecast. 'We probably could have a few rough quarters. I am not saying that we will, but we could,' CEO Elon Musk said. Tesla is grappling with growing challenges, from the rise of lower-cost electric vehicle competitors, especially in China, to a political backlash against Musk that has damaged the brand in the U.S. and Europe. But that hasn't stopped Wood, a longtime supporter of Tesla, from doubling down. 'We've been dealing with controversy around Elon Musk in one form or another since we first bought the stock,' Wood said in a recent interview with Bloomberg. 'We do trust the board and the board's instincts here and we stay out of politics.' She also noted that Musk seems more focused on the business again, especially after he decided to take charge of sales in the US and Europe. 'One of the announcements Elon made recently is that he is going to oversee sales in the US and in Europe,' Wood said. 'When he puts his mind on something, he usually gets the job done. So I think he's much less distracted now than he was, let's say, in the White House 24/7.' Back in March, Wood predicted Tesla's stock would reach $2,600 in five years, which is nearly nine times higher than where it trades now. Much of the optimism is driven by the company's highly anticipated robotaxi, which Wood believes will account for 90% of the company's value. Musk said during the earnings call that Tesla's robotaxi service, which the company has recently started testing in Austin, Texas, will expand to other states, with a goal of covering half the U.S. population by year-end pending regulatory approvals. "That's at least our goal, subject to regulatory approvals. I think we will technically be able to do it," he said. Tesla stock is down more than 21% year-to-date. The stock has long been Wood's biggest holding, accounting for 9.6% of the Ark Innovation Wood buys $45 million of battered megacap tech stock first appeared on TheStreet on Jul 27, 2025 This story was originally reported by TheStreet on Jul 27, 2025, where it first appeared. Sign in to access your portfolio

2 Healthcare Stocks That Are Losing to the S&P 500 This Year
2 Healthcare Stocks That Are Losing to the S&P 500 This Year

Yahoo

time34 minutes ago

  • Yahoo

2 Healthcare Stocks That Are Losing to the S&P 500 This Year

Key Points Novo Nordisk and Regeneron have encountered challenges recently. Both companies are significantly trailing the market this year. These healthcare leaders still could perform well in the long run. 10 stocks we like better than Novo Nordisk › Even with all the volatility and the flirting with bear-market territory, the S&P 500 index is well in the green this year, up about 8% since early January. Some stocks haven't been so lucky, though. Novo Nordisk (NYSE: NVO) and Regeneron Pharmaceuticals (NASDAQ: REGN), two leading drugmakers, have underperformed for most of the year, significantly lagging the broader market. These healthcare giants are facing some headwinds, but does that mean investors should steer clear of them? Let's find out. 1. Novo Nordisk Novo Nordisk has been facing several challenges that predate this year. It encountered a clinical setback for what Wall Street thought was a promising weight management candidate. Furthermore, the company's financial results, although strong when compared to its similarly sized peers, were not seen as sufficient because it's held to a higher standard. These challenges have led to a terrible performance this year. Novo Nordisk's shares are down by 18% year to date, significantly lagging the S&P 500. However, the stock might be a steal right now. The company has made several moves that should allow it to recover. Novo Nordisk's pipeline, especially in diabetes and weight management, remains one of the strongest in the industry. It recently initiated a phase 3 study for amycretin -- its next-generation GLP-1 medicine -- in both subcutaneous and oral formulations. It requested regulatory approval in the U.S. for an oral version of semaglutide, its well-known medicine marketed as Wegovy for weight loss and as Ozempic for diabetes management. Novo Nordisk has also penned several licensing deals that have expanded its pipeline in weight management. The company should launch at least one new medicine in its core therapeutic area within the next few years. Financial results should remain strong as Ozempic and Wegovy continue driving solid revenue growth. Considering the stock's sell-off over the past years, shares now look more than reasonably valued relative to Novo Nordisk's growth potential. Their forward price-to-earnings ratio of 16.9 is in line with the healthcare industry's average of 16.5 as of this writing. However, Novo Nordisk typically grows its revenue and earnings faster than its peers. That makes its stock attractive at current levels, based on its growth potential. 2. Regeneron Pharmaceuticals Regeneron is facing biosimilar competition for Eylea, a medicine for wet age-related macular degeneration that was once one of its biggest growth drivers. Sales of the medicine have dropped, dragging total revenue down with them. That's the most important reason why Regeneron's shares are down by 19% since the year started. However, the stock is still attractive. The biotech might go through a period of its top line declining, but it can still recover. Here are three reasons why. First, the company's newer, higher-dose (HD) formulation of Eylea is taking market share away from its previous version. HD Eylea is performing well and will grow even faster once it earns some label expansions. Second, Regeneron has a deep pipeline that's expected to yield new brand approvals. Earlier this month, it earned the green light for Lynozyfic, a cancer medicine, in the U.S. One of its more promising candidates is a gene therapy for one type of genetic deafness, which is showing incredible potential in clinical trials. Regeneron should move beyond Eylea thanks to newer approvals. Third, the company's most important product, Dupixent, an eczema treatment, is performing exceptionally well. The medicine has earned important label expansions in recent years, including in treating chronic obstructive pulmonary disease (COPD) and a rare skin condition called bullous pemphigoid. Dupixent will maintain its upward growth trajectory for a while. Here's one more reason to invest in Regeneron: The company is committed to returning capital to shareholders. It recently initiated a dividend and has a robust share-buyback program in place. The stock might be moving in the wrong direction right now, but those willing to hold onto it for five years or more could see superior returns over the long run. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Prosper Junior Bakiny has positions in Novo Nordisk. The Motley Fool has positions in and recommends Regeneron Pharmaceuticals. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Are Losing to the S&P 500 This Year was originally published by The Motley Fool Connectez-vous pour accéder à votre portefeuille

3 Vanguard ETFs That Can Turn $500 per Month Into Over $1 Million
3 Vanguard ETFs That Can Turn $500 per Month Into Over $1 Million

Yahoo

time34 minutes ago

  • Yahoo

3 Vanguard ETFs That Can Turn $500 per Month Into Over $1 Million

Key Points These three Vanguard ETFs have delivered exceptional returns since inception. Investing $500 per month while obtaining those historical returns would grow to $1 million in 24 years or less. However, there's no guarantee that these ETFs will generate such lofty returns over the next several decades. 10 stocks we like better than Vanguard S&P 500 ETF › What's the most important secret to becoming a successful chef? Knowing the right ingredients to use. I think this is also the secret to becoming a successful investor. The primary ingredients of investing are capital, time, and solid investment assets. How much money you can make depends on how much money you have to invest, how much time you have, and which assets you invest in. Exchange-traded funds (ETFs) rank among the best investment assets for long-term investors. And Vanguard offers some of the most attractive ETFs around. Here are three Vanguard ETFs that can turn $500 per month into over $1 million. 1. Vanguard S&P 500 ETF I think the easiest choice to amass a $1 million fortune is the Vanguard S&P 500 ETF (NYSEMKT: VOO). As its name indicates, this ETF aims to track the performance of the S&P 500 (SNPINDEX: ^GSPC), which includes the 500 largest U.S. companies. Over the long run, the S&P 500 has delivered an average annual total return (with dividends reinvested) of around 10%. If you invested $500 per month and achieved that return, you'd have nearly $1.09 million at the end of 30 years. At the end of 40 years, your portfolio would be worth more than $2.9 million. These amounts, by the way, assume that you invest in a tax-advantaged account, such as an individual retirement account (IRA), and don't pull any money out along the way. Granted, the Vanguard S&P 500 ETF hasn't been around for 30 or 40 years. Vanguard launched the fund in September 2010. Since its inception, the ETF has delivered an average annual total return of 13.6%. If you were able to make this higher return, your $500 per month would grow to over $1 million in only 24 years. After 30 years, you'd amass a fortune of over $2.2 million. There's no guarantee that the Vanguard S&P 500 ETF will generate an average return of 13.6% -- or even 10%. However, those returns are certainly possible. One of the advantages of the S&P 500 is that it regularly replaces laggards with rising stars. It's also weighted by market cap, which means the stocks that grow the most affect the index's performance the most. 2. Vanguard S&P 500 Growth ETF If the S&P 500 can achieve 10% returns over the long term, it stands to reason that the fastest-growing stocks in the index could deliver even greater returns. That's the premise behind the Vanguard S&P 500 Growth ETF (NYSEMKT: VOOG). This Vanguard ETF focuses only on growth stocks in the S&P 500. It currently owns 212 stocks, instead of the 505 stocks in the Vanguard S&P 500 ETF (this number is greater than 500 because some companies have multiple classes of shares). Since its inception in September 2010, the Vanguard S&P 500 Growth ETF has generated an average annual return of 16.4%. If you were able to obtain this return and invested $500 per month, your money would grow to a little over $4 million in 30 years. You'd have $1 million within 22 years. Can the Vanguard S&P 500 Growth ETF continue to deliver such a lofty return over the next several decades? Probably not. However, I think this fund could nonetheless turn $500 per month into over $1 million for those who begin investing at an early age. 3. Vanguard Russell 1000 Growth ETF Let's expand our horizons somewhat. What if, instead of limiting ourselves to the growth stocks in the S&P 500, we invested in growth stocks in an index that held more stocks? The Vanguard Russell 1000 Growth ETF (NASDAQ: VONG) could be just the ticket. This ETF attempts to track the performance of growth stocks in the Russell 1000 index. Whereas the S&P 500 owns shares of the 500 largest U.S. companies, the Russell 1000 owns shares of the largest 1,000 companies. The Vanguard Russell 1000 Growth ETF's portfolio currently includes 387 stocks. Like the other two ETFs on our list, this Vanguard ETF began trading in September 2010. Since its inception, the fund has generated an average annual return of 16.9%. That makes it the best-performing ETF in the Vanguard family. How long would it take to make $1 million investing $500 per month at that return? Less than 21 years. If you kept socking away money for 30 years, you'd have nearly $4.5 million. Again, there's no way to know for sure whether the Vanguard Russell 1000 Growth ETF will provide such a sky-high return over the long term. I wouldn't count on it. But this Vanguard ETF could still provide a great vehicle for investors to make $1 million or more for retirement. Should you buy stock in Vanguard S&P 500 ETF right now? Before you buy stock in Vanguard S&P 500 ETF, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Vanguard S&P 500 ETF wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Vanguard S&P 500 ETF. The Motley Fool has a disclosure policy. 3 Vanguard ETFs That Can Turn $500 per Month Into Over $1 Million was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store